HormoneResearch Phase

Mod GRF 1-29 (CJC-1295 no DAC)

Subcutaneous injection

Overview

Modified GRF 1-29 is a synthetic analogue of growth hormone releasing hormone (GHRH) comprising 29 amino acids with four amino acid substitutions to enhance stability. These modifications increase resistance to enzymatic degradation compared to native GHRH while maintaining receptor affinity and biological activity.

Mechanism of Action

The compound stimulates pulsatile growth hormone release from the anterior pituitary without the half-life extension conferred by drug affinity complex technology..

Research Summary & Key Findings

Preclinical studies have demonstrated enhanced growth hormone secretion and improved pharmacokinetic stability relative to native GHRH. No formal clinical trials have been published in peer-reviewed literature, and the compound lacks regulatory evaluation by major health authorities. Its use has been primarily documented in performance enhancement contexts outside approved therapeutic settings.

Clinical Status

Research Phase

Mod GRF 1-29 (CJC-1295 no DAC) is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.

Administration Routes

Subcutaneous injection

Related Peptides in Hormone

CJC-1295

In Clinical Trials

A synthetic analog of growth hormone-releasing hormone (GHRH) with a Drug Affinity Complex (DAC) that binds to albumin, ...

View details

Ipamorelin

In Clinical Trials

A highly selective growth hormone secretagogue that acts on ghrelin/GHS receptors in the pituitary gland to stimulate GH...

View details

Sermorelin

FDA Approved

A synthetic 29-amino acid analog of GHRH representing the shortest fully functional fragment of the native 44-amino acid...

View details

Tesamorelin (Egrifta)

FDA Approved

A synthetic GHRH analog consisting of the 44-amino acid sequence of human GHRH with a trans-3-hexenoic acid modification...

View details

Find a Provider

Find a verified provider who offers Mod GRF 1-29 (CJC-1295 no DAC) therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Mod GRF 1-29 (CJC-1295 no DAC).

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.